MA28871B1 - Derives tricycliques accoles pour le traitement de troubles psychotiques - Google Patents

Derives tricycliques accoles pour le traitement de troubles psychotiques

Info

Publication number
MA28871B1
MA28871B1 MA29771A MA29771A MA28871B1 MA 28871 B1 MA28871 B1 MA 28871B1 MA 29771 A MA29771 A MA 29771A MA 29771 A MA29771 A MA 29771A MA 28871 B1 MA28871 B1 MA 28871B1
Authority
MA
Morocco
Prior art keywords
accurate
treatment
psychotic disorders
tricyclic derivatives
tricyclic
Prior art date
Application number
MA29771A
Other languages
English (en)
Inventor
Jonathan Bentley
Markus Bergauer
Barbara Bertani
Matteo Biagetti
Manuela Borriello
Steven Mark Bromidge
Massimo Gianotti
Enrica Granci
Colin Philip Leslie
Alessandra Pasquarello
Valeria Zucchelli
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0419315A external-priority patent/GB0419315D0/en
Priority claimed from GB0507386A external-priority patent/GB0507386D0/en
Priority claimed from GB0515010A external-priority patent/GB0515010D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28871B1 publication Critical patent/MA28871B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA29771A 2004-08-31 2007-03-23 Derives tricycliques accoles pour le traitement de troubles psychotiques MA28871B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0419315A GB0419315D0 (en) 2004-08-31 2004-08-31 Compounds
GB0507386A GB0507386D0 (en) 2005-04-12 2005-04-12 Compounds
GB0515010A GB0515010D0 (en) 2005-07-21 2005-07-21 Compounds

Publications (1)

Publication Number Publication Date
MA28871B1 true MA28871B1 (fr) 2007-09-03

Family

ID=35106764

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29771A MA28871B1 (fr) 2004-08-31 2007-03-23 Derives tricycliques accoles pour le traitement de troubles psychotiques

Country Status (17)

Country Link
US (1) US20120022056A1 (fr)
EP (1) EP1786822A1 (fr)
JP (1) JP2008511574A (fr)
KR (1) KR20070057885A (fr)
CN (1) CN101048414B (fr)
AR (1) AR053307A1 (fr)
AU (1) AU2005279278A1 (fr)
BR (1) BRPI0514377A (fr)
CA (1) CA2578781A1 (fr)
IL (1) IL181387A (fr)
MA (1) MA28871B1 (fr)
MX (1) MX2007002548A (fr)
NO (1) NO20071326L (fr)
NZ (1) NZ553506A (fr)
PE (1) PE20060653A1 (fr)
TW (1) TW200619221A (fr)
WO (1) WO2006024517A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7898642B2 (en) 2004-04-14 2011-03-01 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method
CN101296914B (zh) 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
CA2636043A1 (fr) * 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Inhibiteurs tricycliques de la 5-lipoxygenase
US7501438B2 (en) 2006-07-07 2009-03-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
MX2009002121A (es) 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
US20100004452A1 (en) 2006-09-26 2010-01-07 Barbara Bertani 5-quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairment, psychotic disorders, anxiety, depression, etc.
AU2008223348A1 (en) * 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
EP2070933A1 (fr) * 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Composants triazoliques tricycliques
GB0800840D0 (en) 2008-01-17 2008-02-27 Glaxo Group Ltd Novel salt
AU2009221179A1 (en) 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2415767B1 (fr) * 2009-03-27 2014-09-03 Takeda Pharmaceutical Company Limited Inhibiteurs de la poly(ADP-ribose)polymérase (PARP)
AU2011217206A1 (en) 2010-02-19 2012-08-02 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
WO2011153359A1 (fr) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Inhibiteurs du transporteur 1 de la glycine, procédés de fabrication associés, et utilisations associées
WO2012154731A1 (fr) * 2011-05-08 2012-11-15 Vanderbilt University Analogues de 1h-pyrrolo[3,2-c]quinoléine-4(5h)-one substitués utilisés comme modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
EP2760868B1 (fr) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Dérivés de furo[3,4-c]quinoléine, médicaments contenant ces composés, leur utilisation et procédé de leur préparation
EP2792679A1 (fr) * 2013-04-19 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Composants triazoliques tricycliques
EP3013823B1 (fr) * 2013-06-24 2017-11-01 Merck Patent GmbH Composés imidazole servant de modulateurs des récepteurs de la fshr et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
IL124914A (en) * 1997-06-26 2000-10-31 Akzo Nobel Nv Pharmaceutical compositions containing 6-aryl-2,3,5,6-tetrahydroimidazo¬2,1-a¾isoquinoline derivatives and some new such compounds
US6919334B2 (en) * 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
AR053307A1 (es) 2007-05-02
PE20060653A1 (es) 2006-09-27
MX2007002548A (es) 2007-04-24
CN101048414B (zh) 2011-09-07
US20120022056A1 (en) 2012-01-26
CN101048414A (zh) 2007-10-03
NZ553506A (en) 2010-02-26
IL181387A0 (en) 2007-07-04
NO20071326L (no) 2007-05-03
AU2005279278A1 (en) 2006-03-09
TW200619221A (en) 2006-06-16
KR20070057885A (ko) 2007-06-07
WO2006024517A1 (fr) 2006-03-09
CA2578781A1 (fr) 2006-03-09
BRPI0514377A (pt) 2008-06-24
JP2008511574A (ja) 2008-04-17
EP1786822A1 (fr) 2007-05-23
IL181387A (en) 2011-10-31

Similar Documents

Publication Publication Date Title
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
MA28555B1 (fr) Derives de morpholine substitues pour le traitement de troubles du systeme nerveux central
NO20071326L (no) Kondenserte trisykliske derivater for behandling av psykotiske forstyrrelser
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
EP2096919A4 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP2063889A4 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer
HUS1800041I1 (hu) Piperazinnal helyettesített benzotiofének mentális rendellenességek kezelésére
EP1838320A4 (fr) Antagonistes de cxcr4 pour le traitement de troubles medicaux
EP1601251A4 (fr) Compos s pour le traitement de troubles m taboliques
EP1931691A4 (fr) Inhibiteurs d'odcase pour le traitement du paludisme
EP1773226A4 (fr) Dispositifs électriques pour le traitement de défauts anatomiques
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ZA200801888B (en) Derivatives of 4-piperazin-1-1-YL-4-benzo [B] thiophene suitable for the treatment of CNS disorders
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
EP1881823A4 (fr) Compositions et procedes pour le traitement des troubles oculaires
IS2907B (is) Bensó[d]asepínafleiður til að meðhöndla taugakvilla
EP2225196A4 (fr) Inhibiteurs de cystéine-protéases pour le traitement de maladies parasitaires
NO20054317D0 (no) Fremgangsmate for homogenisering av polyolefin-DRA-midler
EP1758854A4 (fr) Composes pyrrolidin-3-yle utiles en tant qu'inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
EP1804787A4 (fr) Composition flavonoide pour le traitement des maladies bucco-dentaires
EP1951261A4 (fr) Préparations et méthodes pour le traitement de troubles inflammatoires
EP1933813A4 (fr) Liposomes de sphingomyeline pour le traitement de troubles de vessie hyperactive
EP1814537A4 (fr) Inhibiteurs de la beta-secretase formes d'amines tertiaires macrocycliques pour le traitement de la maladie d'alzheimer
EP1855682A4 (fr) Formes posologiques d'aminopterine et methodes pour troubles inflammatoires